Rovi stock sits 33.41 percent below its 52-week high at EUR 57.73
Published on 10/20/2026 at 10:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSRovi balances growth and dates
- First-half revenue rose 13.00 percent to EUR 357.00 million in 2026.
- Contract manufacturing revenue increased 38.00 percent to EUR 106.30 million in the first half of 2026.
- Rovi stock trades at EUR 57.73 at 10:41 a.m. CEST at Lang & Schwarz on October 20, 2026, below its 52-week high.
Rovi stock (ISIN ES0157261019) was trading at EUR 57.73 at Lang & Schwarz on October 20, 2026 at 10:41 a.m. CEST, 33.41 percent below its 52-week high of EUR 86.70. The latest reported figures show first-half revenue of EUR 357.00 million, up 13.00 percent year over year, while the next reporting date is November 5, 2026.
Growth is led by manufacturing
Rovi's first-half operating revenue reached EUR 344.20 million, an increase of 9.00 percent from the first half of 2025, according to Yahoo Finance. The contract manufacturing business grew 38.00 percent to EUR 106.30 million, making the CDMO division the clearest operating growth engine in the period.
Reported EBITDA rose 85.00 percent to EUR 121.20 million in the first half of 2026. The comparison includes a EUR 62.40 million bargain purchase gain linked to the Phoenix manufacturing facility acquisition, so EBITDA excluding that item fell 10.00 percent to EUR 58.80 million.
What does CDMO growth add?
The manufacturing expansion changes the earnings mix. Rovi said Phoenix revenue contributed to the first-half performance after the acquisition closed on April 1, 2026, while a supply agreement provides a baseline of USD 50.00 million in annual revenue, according to Yahoo Finance. The Phoenix line is expected to become operational between the end of 2027 and early 2028.
Three dates shape the next view
On April 1, 2026, Rovi completed the Phoenix facility acquisition and recognized the EUR 62.40 million bargain purchase gain. On July 23, 2026, it reported first-half revenue of EUR 357.00 million and maintained its 2026 operating-revenue outlook. On September 1, 2026, Rovi announced its nine-month results date of November 5, 2026, as reported by Simply Wall St.
Upcoming reporting dates
Rovi's next scheduled event is the first nine months 2026 financial results on November 5, 2026, according to Rovi. Barron's also lists the fiscal-year 2026 results for February 24, 2027.
Stock remains below its yearly high
The current EUR 57.73 quote is below the EUR 86.70 52-week high and above the EUR 53.10 low listed for Rovi on October 19, 2026. The company had a market capitalization of EUR 3.0 billion as of October 20, 2026, while the latest analyst compilation cited an average target of EUR 75.85.
Rovi was trading at EUR 57.73 at Lang & Schwarz on October 20, 2026 at 10:41 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Rovi stock.
Rovi stock facts
- Company: Laboratorios Farmaceuticos Rovi, S.A.
- ISIN: ES0157261019
- Ticker: ROVI.MC
- Primary exchange: BME
- Price Lang & Schwarz (as of October 20, 2026, 10:41 a.m. CEST): EUR 57.73
- 52-week range: EUR 53.10-EUR 86.70 (as of October 19, 2026)
- Market capitalization: EUR 3.0 billion (as of October 20, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
Market context: Market report IBEX 35.
